去纤苷作用及价格

Function:

Defibrinoside is a polydeoxyribose ribonate that has certain fibrinolytic and antithrombotic activities and can promote the production of prostacyclin-like substances and release them from vascular tissues into the circulation. This medicine is indicated for the treatment of adult and pediatric patients with hepatic venous occlusion (VOD) and associated renal or pulmonary abnormalities after blood or bone marrow hematopoietic stem cell transplantation (HSCT).

The approval was based on a Phase 2 trial of 75 patients, a Phase 3 trial of 102 patients, and an expansion trial of an additional 351 patients. All patients in the trial were diagnosed with hepatic venule occlusion accompanied by renal or pulmonary dysfunction after HSCT. In the phase 2 trial, 44% of patients survived 100 days after transplantation, compared with 38% in the phase 3 trial and 45% in the expanded trial, and the FDA noted in a report that the expected 100-day survival rate for patients with severe hepatic venule occlusion without defibrotide treatment was 21%-31%.

Data on the safety of defibrotide are based on 176 patients. The most common adverse reactions include hypotension, diarrhea, vomiting, nausea, and epistaxis. The most common serious adverse reactions include hypotension and alveolar hemorrhage. The approval of defibrotide greatly meets the treatment needs of transplant patients suffering from such rare and fatal complications.

Defibrotide is currently the only FDA-approved treatment for adult and pediatric patients who develop hepatic venule occlusion (VOD) and associated renal or pulmonary abnormalities after blood or bone marrow hematopoietic stem cell transplantation (HSCT).

Defibrinoside price:

According to Medical Companion Travel, it has been marketed abroad. The price of defibrinoside listed abroad is about 22,000. Due to the floating exchange rate, the price is different. Please consult Medical Companion Travel for the specific price! 

Recommended related hot articles: /newsDetail/74982.html